The Food and Drugs Authority (FDA) has rescinded the GMP certification of Aveo Pharmaceuticals, an Indian drug manufacturer, over its alleged involvement in the unlawful distribution of opioid-based medications in West Africa.

This action follows a BBC Africa Eye investigation that uncovered how Aveo Pharmaceuticals, through Westfin International, was reportedly shipping unauthorized drugs containing tapentadol and carisoprodol to nations such as Ghana, Nigeria, and Côte d’Ivoire.

These substances are classified as highly addictive and pose severe health hazards, including respiratory complications and potential fatal overdoses when misused.

In response to the findings, the FDA has instructed Samos Pharma, a pharmaceutical importer in Ghana, to immediately sever all ties with both Aveo Pharmaceuticals and Westfin International.

Furthermore, the approval process for six products linked to Masters Pharmaceutical Limited, which intended to source production from Aveo Pharmaceuticals, has been put on hold.

Reaffirming its resolve to combat opioid abuse, the FDA highlighted its ongoing regulatory measures, including drug seizures, financial penalties, and legal actions against illegal distributors.

The agency assured the public that it will persist in working alongside security agencies to curb the circulation of harmful pharmaceuticals.

This latest move strengthens Ghana’s regulatory enforcement against illicit drug trade while reinforcing measures to protect public safety.